Phase 3 N=523 PreHospital Air Medical Plasma Trial
Hemmorhagic Shock During Air Medical Transport
Primary: Our Primary Outcome for the Proposal Will be 30 Day Mortality — 53; 89 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Smart Capsule for Automatic Adherence Monitoring
Medication Adherence
Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)
Phase 1 N=17 A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of S-Warfarin — 132; 126 nanograms*hour/milliliter (ng*h/mL)
Phase 3 N=249 Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression
Benign Prostatic Hyperplasia
Primary: Change in Total IPSS Scores (International Prostate Symptome Score) After 1, 3, 6 and 12 Months Compared to Baseline. — -1.3; -0.6; -2.3; -1.5 Scores on a scale — p=0.0005
Phase 3 N=104 ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
Chronic Hepatitis C Virus (HCV)
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) — 100 percentage of participants
Phase 4 N=240 AngioSeal Versus Radial Approach in Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: First Occurrence of Access Site Related Ischemic or Bleeding Complication — 16; 15 Participants
Phase 1 N=20 A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
Cardiovascular Disease
Primary: Pharmacokinetics (PK): Area Under The Concentration Versus Time Curve From Time Zero To Time Tlast, Where Tlast is the Last Time Point With a Measurable Concentration…
N/A N=30 Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min
Phase 4 N=50 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish
Foot Dermatoses
Primary: Measurement of Antifungal Activity of Loceryl Nail Lacquer — 53.6; 53.5 Milimeter
N/A N=53 PackHealth: Asthma Engagement Tool
Asthma
Primary: Rate of Asthma Exacerbations — 3.21 events/12 weeks
Phase 1 N=60 A Study of Evacetrapib (LY2484595) in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib (LY2484595) — 604; 597 nanograms per milliliter
N/A N=2,421 Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
Malaria
Primary: Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), by Study Center — 235; 153; 167; 141 Participants
Phase 1 N=16 A Study to Compare Two Forms of LY2608204 in Healthy People
Healthy Volunteers
Primary: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) — 974; 1080 nanogram.hour per milliliter (ng.h/mL)
N/A N=42 Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome
Breast Carcinoma
Primary: Area Under the Curve (AUC) EORTC CIPN20 Sensory Neuropathy Subscale Adjusting for Baseline — -1.4; -4.4 Average(subscale value*assessment) — p=0.26
N/A N=115 Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Arthralgia
Primary: Knee Cartilage Volume — 2042; 1971 mm³